Taro Pharmaceutical Industries Ltd.
TARO
TARO was delisted on the 21st of June, 2024.
84 hedge funds and large institutions have $369M invested in Taro Pharmaceutical Industries Ltd. in 2020 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 26 increasing their positions, 23 reducing their positions, and 10 closing their positions.
60% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 10
41% more capital invested
Capital invested by funds: $262M → $369M (+$108M)
13% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 23
8% more funds holding
Funds holding: 78 → 84 (+6)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $184K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$9.6M |
| 2 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$4.53M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$4.42M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.7M |
| 5 |
State Street
Boston,
Massachusetts
|
+$1.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$4.01M |
| 2 |
APG Asset Management
Amsterdam,
Netherlands
|
-$3.56M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$1.77M |
| 4 |
CAM
Claret Asset Management
Montreal,
Quebec, Canada
|
-$1.4M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$1.29M |
TARO Hedge Fund Activity: Q4 2020 in Review
84 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q4 2020, worth a combined $369M — up 41% from $262M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new TARO positions and 10 closed out — a net gain of 6 holders — while 26 added to existing stakes and 23 trimmed.
The largest buyer was BlackRock, adding an estimated $9.6M. The largest seller was UBS Group, cutting an estimated $4.01M.
- 84 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q4 2020, up from 78 in Q3 2020.
- Funds reported $369M of Taro Pharmaceutical Industries Ltd. stock for Q4 2020, up 41% quarter-over-quarter.
- 16 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q4 2020 and 10 closed out, a net change of +6 holders.
- The largest Taro Pharmaceutical Industries Ltd. buyer in Q4 2020 was BlackRock, an estimated $9.6M added.
- The largest Taro Pharmaceutical Industries Ltd. seller in Q4 2020 was UBS Group, an estimated $4.01M sold.
Based on aggregated 13F filings for Q4 2020.